Abstracts tional study of schizophrenic patients who commence RLAI. Data collected retrospectively (12 months) and prospectively (2 years) includes: patient demographics, medications, hospitalisations, Clinical Global Impression-Severity (CGI-S), GAF and adverse events. A general linear model (GLM) was used to determine the impact of baseline characteristics on GAF improvement over 12 months. RESULTS: Data from 399 patients from 15 psychiatric services were available for this analysis. The average age was 38.9 ± 13.2 years (mean ± SD), the mean duration of illness was 12.0 ± 9.6 years, and 68% were male. The baseline CGI-S was 4.5 ± 1.0 and GAF was 42.4 ± 14.1. The greatest improvements in GAF score occurred in the first 3-months following switch to RLAI, however, significant improvements also occurred between 3-and 6-months (baseline: 42.8 ± 14.3; 3-months 50.3 ± 15.5; 6-months 53.0 ± 15.3, p < 0.001 [0-3 months, and 3-6 months], n = 328). Those patients with baseline GAF scores less than 30 were more likely to show greater improvements in their GAF functioning over the 12-month period Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia OBJECTIVE: To obtain a carer's perspective on the valuation of eight schizophrenia-related health states using two multiattribute utility instruments, the Assessment of Quality of Life Questionnaire (AQoL), and the EQ5D. METHODS: Eight schizophrenia-related health state scenarios based on severity of symptoms and medication side effects were presented to 64 carers of patients with schizophrenia in face-to-face questionnaires. Scenarios were: (A) "good" function with no movement disorders (extrapyramidal symptoms); (B) "good" function with movement disorders; (C) "poor" function with no movement disorders; (D) "poor" function with movement disorders; (E) hospitalised relapse with no movement disorders; (F) hospitalised relapse with movement disorders; (G) post-hospitalisation with no movement disorders; and (H) post-hospitalisation with movement disorders. The carers valued each health state using the AQoL and the EQ5D from the carer and patient perspectives. RESULTS: When carer's were asked to assess their quality of life when the person they cared for was in the various health states, the mean utility values from the AQoL ranged from 0.56 ± 0.26 (SD), for Scenario A, to 0.22 ± 0.25, for Scenario F. Mean utility values for the health states from the EQ5D ranged from 0.76 ± 0.19, for Scenario A, to 0.29 ± 0.42, for Scenario F. When the carer's were asked to assess the health state scenarios from a patient's perspective, the mean utility values from the AQoL ranged from 0.37 ± 0.23, for Scenario A, to 0.04 ± 0.19, for Scenario F. Mean utility values for the health states from the EQ5D ranged from 0.70 ± 0.28, for Scenario A, to 0.03 ± 0.43, for Scenario F. CONCLUSION: From both perspectives, the rank order of utility values was consistent with the severity of symptoms, with more severe symptoms producing lower scores. Scenarios that involved patients experiencing extrapyramidal symptoms or hospitalisation produced lower utility values. prevention and Markov model in primary prevention were used. Population characteristics and outcomes were based on 4S and HPS trials. The analysis in the primary prevention were performed in two groups with 3% and 5% 5-year risk of cardiovascular death (CVD) to comply with EURO-SCORE algorithm. Direct costs of CHD and stroke were projected over lifetime from Polish National Health Fund perspective. Costs, epidemiological data and quality of life weights (primary prevention) were derived from published sources. Costs and effects were discounted at 5% annually. RESULTS: LYG in the secondary prevention was calculated as €365 for 58-year old men and €613 for 60-year old women. Cost of QALY in the primary prevention ranged from €2154 for 50-year old men to €2595 for 65-year old men in the group with 3% risk and from €1544 to €1796 for 5% risk, well within implicit limits at roughly €15,000. Results for women were very close to men but were less robust due to uncertainty in preventing CVD death. CONCLUSION: Reimbursement of simvastatin in Poland is economically justified regardless of age of initiation of The rapy and sex. Raising the level of reimbursement from current 70% to 100% will increase availability for all, who may benefit from The rapy but cannot afford co-payment. The analysis may help to develop guidelines for primary prevention using EURO-SCORE risk system. 
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